Altered patterns of RB expression define groups of soft tissue sarcoma patients with distinct biological and clinical behavior.
Function of the retinoblastoma tumor suppressor protein (pRB) may be compromised at a genetic level by gene loss or mutation or at a post-translational level by hyperphosphorylation. In this study, we examined adult soft tissue sarcomas (ASTS) to determine if alterations of pRB were associated with distinct patterns of pRB expression and clinical outcome.



We investigated 86 ASTS patients using monoclonal antibodies that distinguish between hyperphosphorylated and underphosphorylated pRB products. We also used microsatellite analysis to investigate the genetic status of the RB locus. We correlated pRB alterations with proliferative activity, and with clinicopathological outcomes.



Altered patterns of pRB expression are common in ASTS occurring in 84% of cases, and it is significantly associated with proliferative activity (p<0.001). Patients whose tumors either lack expression of pRB, or express hyperphosphorylated forms of pRB, have poor survivals compared to patients whose tumors exhibit a normal, underphosphorylated pattern of pRB expression (p=0.03). In addition, 63% of cases lacking expression of pRB showed loss-of-heterozygosity at the locus.



Inactivation of pRB is common in adult STS, which may be due to either gene loss or post-translational modification, namely hyper-phosphorylation. Both mechanisms are associated with tumor cell proliferation and poor survival.
Polsky
D
D
Department of Pathology, Memorial Sloan-Kettering Cancer Center, New York, USA. david.polsky@med.nyu.edu
Mastorides
S
S
Kim
D
D
Dudas
M
M
Leon
L
L
Leung
D
D
Woodruff
J M
JM
Brennan
M F
MF
Osman
I
I
Cordon-Cardo
C
C
D014408:Biomarkers, Tumor / Q000378:metabolism; D049109:Cell Proliferation; D015972:Gene Expression Regulation, Neoplastic; D006801:Humans; D007124:Immunoenzyme Techniques; D019656:Loss of Heterozygosity; D018895:Microsatellite Repeats; D010766:Phosphorylation; D011446:Prospective Studies; D016160:Retinoblastoma Protein / Q000378:metabolism*; D012509:Sarcoma / Q000235:genetics / Q000378:metabolism* / Q000401:mortality / Q000473:pathology; D012983:Soft Tissue Neoplasms / Q000235:genetics / Q000378:metabolism* / Q000401:mortality / Q000473:pathology; D015996:Survival Rate
D014408:Biomarkers, Tumor; D016160:Retinoblastoma Protein